title: Epidemiology and outcomes of candidemia in 3648 patients: data from the Prospective Antifungal Therapy (PATH Alliance®) registry, 2004-2008.
abstract: This analysis describes the epidemiology and outcomes of candidemia in patients enrolled in the Prospective Antifungal Therapy Alliance (PATH Alliance®) registry from 2004 to 2008. Overall, 4067 Candida isolates were identified from 3648 patients. The most common Candida spp. were C. albicans (42.1%), C. glabrata (26.7%), C. parapsilosis (15.9%), C. tropicalis (8.7%), and C. krusei (3.4%). The proportion of candidemia caused by non-albicans Candida spp. (57.9%) was higher than that caused by C. albicans (42.1%). Infections with C. albicans were most common in neonatal intensive care unit (54.8%). In total, 3342 patients received antifungal therapy; fluconazole (66.0%) and echinocandins (50.5%) were most frequently administered. The 90-day survival rate for all patients was 61.3%. Among the most common Candida spp., the highest 90-day survival rate was observed for C. parapsilosis (70.0%) and the lowest for C. krusei (53.6%). In conclusion, this study expands the current knowledge of the epidemiology and outcomes of candidemia.
authors.affiliation: JMI Laboratories, North Liberty, IA 52317, USA. michael-pfaller@jmilabs.com
authors.forename: Michael
authors.initials: M
authors.lastname: Pfaller
authors.forename: Dionissios
authors.initials: D
authors.lastname: Neofytos
authors.forename: Daniel
authors.initials: D
authors.lastname: Diekema
authors.forename: Nkechi
authors.initials: N
authors.lastname: Azie
authors.forename: Herwig-Ulf
authors.initials: HU
authors.lastname: Meier-Kriesche
authors.forename: Shun-Ping
authors.initials: SP
authors.lastname: Quan
authors.forename: David
authors.initials: D
authors.lastname: Horn
mesh_terms: D000935:Antifungal Agents / Q000008:administration & dosage*; D002175:Candida / Q000145:classification / Q000187:drug effects / Q000302:isolation & purification*; D058387:Candidemia / Q000188:drug therapy* / Q000453:epidemiology* / Q000382:microbiology; D006801:Humans; D011446:Prospective Studies; D016019:Survival Analysis; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents